Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

With U.S. biosimilar competition targeting two of its top-selling oncology meds, Herceptin and Avastin, Roche is already facing a tough road ahead. But now, with Teva and Celltrion's Rituxan biosim ready for shelves, Roche's worst-case scenario has officially arrived.